1,5-bis-N-aziridinopentane | 40717-38-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1,5-bis-N-aziridinopentane
• 英文别名: 1,1'-(Pentane-1,5-diyl)bis(aziridine)；1-[5-(aziridin-1-yl)pentyl]aziridine
• CAS: 40717-38-2
• 化学式: C₉H₁₈N₂
• 分子量: 154.255
• InChiKey: FXLCTSUPNWYPFW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  11
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  6
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  1,5-二氨基戊烷 、 1,2-二溴乙烷 在 sodium hydroxide 作用下， 以 苯 为溶剂， 反应 12.0h， 以27%的产率得到1,5-bis-N-aziridinopentane
  参考文献：
  名称：

  ?,?-Bis-N-aziridinoalkanes

  摘要：

  By reactions of alpha, omega-diamines with 1,2-dihaloethanes there were synthesized alpha,omega-bis-N-aziridinoalkanes (1a-g) and bis-N-aziridinoethyl ether (II). From 1,3-diaminopropane and dichloroethane bis-aziridine (III) was isolated in addition to (Ia). NMR spectra of the products were studied.

  DOI：

  10.1007/bf00958573

文献信息

• Use of metabolic phenotyping in individualized treatment with amonafide
  申请人：McGill University

  公开号：US20030190671A1

  公开（公告）日：2003-10-09

  The invention relates to the individualization of therapy on the basis of a phenotypic profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with the drug, amonafide.

  该发明涉及根据个体的表型特征个性化治疗。更具体地说，本发明涉及利用代谢表型来个性化阿莫那非德药物治疗。
• Multiple determinants for metabolic phenotypes
  申请人：——

  公开号：US20030091975A1

  公开（公告）日：2003-05-15

  The invention relates to the determination of multiple phenotypic determinants for human drug metabolizing enzymes. More specifically, the present invention relates to the characterization of metabolic phenotypes based on phenotypic determinants and applications and uses thereof.

  这项发明涉及确定人类药物代谢酶的多个表型决定因素。更具体地说，本发明涉及基于表型决定因素对代谢表型进行表征以及其应用和用途。
• Individualization of therapy with anxiolitics
  申请人：McGill University

  公开号：US20030175210A1

  公开（公告）日：2003-09-18

  The invention relates to the individualization of therapy on the basis of a phenotypic profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with anxiolitic agents.

  本发明涉及基于个体表型特征的治疗个体化。更具体地说，本发明涉及利用代谢表型特征来个体化治疗抗焦虑药物。
• Individualization of therapy with antipsychotics
  申请人：McGill University

  公开号：US20030170176A1

  公开（公告）日：2003-09-11

  The invention relates to the individualization of therapy on the basis of a phenotypic profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with antipsychotic agents.

  本发明涉及基于个体表型特征进行治疗个体化的技术。更具体地说，本发明涉及利用代谢表型特征个体化抗精神病药物治疗的方法。
• Individualization of therapy with antihistamines
  申请人：Xanthus Life Sciences, Inc.

  公开号：US20030180823A1

  公开（公告）日：2003-09-25

  The invention relates to the individualization of therapy on the basis of a phenotypic profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with antihistamines.

  本发明涉及根据个体的表型特征进行治疗个性化的方法。更具体地说，本发明涉及利用代谢表型为抗组胺药物治疗个性化的方法。